{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:56:47Z","timestamp":1761807407023},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,26]],"date-time":"2008-04-26T00:00:00Z","timestamp":1209168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s10549-008-0010-9","type":"journal-article","created":{"date-parts":[[2008,4,25]],"date-time":"2008-04-25T17:25:17Z","timestamp":1209144317000},"page":"371-376","source":"Crossref","is-referenced-by-count":30,"title":["HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis"],"prefix":"10.1007","volume":"114","author":[{"given":"Weiyang","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifa","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongchi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,26]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2003.12.014","volume":"209","author":"S Tommasi","year":"2004","unstructured":"Tommasi S, Fedele V, Lacalamita R et al (2004) Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 209:215\u2013222","journal-title":"Cancer Lett"},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/12.suppl_1.S23","volume":"12","author":"T Cooke","year":"2001","unstructured":"Cooke T, Reeves J, Lanigan A et al (2001) HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12:S23\u2013S28","journal-title":"Ann Oncol"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","volume":"8","author":"JS Ross","year":"2003","unstructured":"Ross JS, Fletcher JA, Linette GP et al (2003) The Her-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307\u2013325","journal-title":"Oncologist"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"R357","DOI":"10.1186\/bcr1004","volume":"7","author":"SE Nelson","year":"2005","unstructured":"Nelson SE, Gould MN, Hampton JM (2005) A case\u2013control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:R357\u2013R364","journal-title":"Breast Cancer Res"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1093\/nar\/19.19.5452-a","volume":"19","author":"J Papewalis","year":"1991","unstructured":"Papewalis J, Nikitin AYu, Rajewsky MF (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2\/HER2 gene. Nucleic Acids Res 19:5452","journal-title":"Nucleic Acids Res"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jnci\/92.5.412","volume":"92","author":"D Xie","year":"2000","unstructured":"Xie D, Shu XO, Deng Z et al (2000) Population-based, case\u2013control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412\u2013417","journal-title":"J Natl Cancer Inst"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/jnci\/94.23.1807","volume":"94","author":"A Hishida","year":"2002","unstructured":"Hishida A, Hamajima N, Iwata H et al (2002) Re: Population-based, case\u2013control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807\u20131808","journal-title":"J Natl Cancer Inst"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1024068525763","volume":"79","author":"R Millikan","year":"2003","unstructured":"Millikan R, Eaton A, Worley K et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and Whites. Breast Cancer Res Treat 79:355\u2013364","journal-title":"Breast Cancer Res Treat"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3835(01)00671-1","volume":"173","author":"C Keshava","year":"2001","unstructured":"Keshava C, McCanlies EC, Keshava N et al (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37\u201341","journal-title":"Cancer Lett"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/93.7.557","volume":"93","author":"SW Baxter","year":"2001","unstructured":"Baxter SW, Campbell IG (2001) Re: Population-based, case\u2013control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:557\u2013559","journal-title":"J Natl Cancer Inst"},{"key":"10_CR11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/jnci\/93.21.1657","volume":"93","author":"S Wang-Gohrke","year":"2001","unstructured":"Wang-Gohrke S, Chang-Claude J (2001) Re: Population-based, case\u2013control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:1657\u20131659","journal-title":"J Natl Cancer Inst"},{"key":"10_CR12","first-page":"1109","volume":"12","author":"KG Montgomery","year":"2003","unstructured":"Montgomery KG, Gertig DM, Baxter SW et al (2003) The HER2 I655V polymorphism and risk of breast cancer in women <age 40\u00a0years. Cancer Epidemiol Biomarkers Prev 12:1109\u20131111","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.yexmp.2003.12.005","volume":"76","author":"E Akisik","year":"2004","unstructured":"Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260\u2013263","journal-title":"Exp Mol Pathol"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.cej.0000130015.91525.c7","volume":"13","author":"D Pinto","year":"2004","unstructured":"Pinto D, Vasconcelos A, Costa S et al (2004) HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13:177\u2013181","journal-title":"Eur J Cancer Prev"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2004.04.007","volume":"215","author":"E Kamali-Sarvestani","year":"2004","unstructured":"Kamali-Sarvestani E, Talei AR, Merat A (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83\u201387","journal-title":"Cancer Lett"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1827.2005.01789.x","volume":"55","author":"HJ An","year":"2005","unstructured":"An HJ, Kim NK, Oh D et al (2005) Her2 genotype and breast cancer progression in Korean women. Pathol Int 55:48\u201352","journal-title":"Pathol Int"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.fpc.0000166822.66754.c6","volume":"15","author":"DG Cox","year":"2005","unstructured":"Cox DG, Hankinson SE, Hunter DJ (2005) The erbB2\/HER2\/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 15:447\u2013450","journal-title":"Pharmacogenet Genomics"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/carcin\/bgh342","volume":"26","author":"B Frank","year":"2005","unstructured":"Frank B, Hemminki K, Wirtenberger M et al (2005) The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 26:643\u2013647","journal-title":"Carcinogenesis"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2004.11.025","volume":"222","author":"TG Kalemi","year":"2005","unstructured":"Kalemi TG, Lambropoulos AF, Gueorguiev M et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57\u201365","journal-title":"Cancer Lett"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.bjc.6603473","volume":"95","author":"PR Benusiglio","year":"2006","unstructured":"Benusiglio PR, Pharoah PD, Smith PL et al (2006) HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 95:1689\u20131695","journal-title":"Br J Cancer"},{"key":"10_CR21","first-page":"49","volume":"53","author":"P Z\u00fabor","year":"2006","unstructured":"Z\u00fabor P, Vojvodov\u00e1 A, Danko J et al (2006) HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case\u2013control study in Slovakia. Neoplasma 53:49\u201355","journal-title":"Neoplasma"},{"key":"10_CR22","first-page":"365","volume":"54","author":"E Papadopoulou","year":"2007","unstructured":"Papadopoulou E, Simopoulos K, Tripsianis G et al (2007) Allelic imbalance of HER-2 codon 655 polymorphism among different religious\/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma 54:365\u2013373","journal-title":"Neoplasma"},{"key":"10_CR23","first-page":"241","volume":"29","author":"S Tommasi","year":"2007","unstructured":"Tommasi S, Fedele V, Lacalamita R et al (2007) 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol 29:241\u2013248","journal-title":"Cell Oncol"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clinbiochem.2007.11.005","volume":"41","author":"SC Lee","year":"2008","unstructured":"Lee SC, Hou MF, Hsieh PC et al (2008) A case\u2013control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem 41:121\u2013125","journal-title":"Clin Biochem"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10549-004-2171-5","volume":"89","author":"RC Millikan","year":"2005","unstructured":"Millikan RC, Hummer AJ, Wolff MS et al (2005) HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case\u2013control analyses. Breast Cancer Res Treat 89:309\u2013312","journal-title":"Breast Cancer Res Treat"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2288-6-50","volume":"6","author":"L Bax","year":"2006","unstructured":"Bax L, Yu LM, Ikeda N et al (2006) Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 6:50","journal-title":"BMC Med Res Methodol"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/bcr982","volume":"7","author":"PR Benusiglio","year":"2005","unstructured":"Benusiglio PR, Lesueur F, Luccarini C et al (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case\u2013control study. Breast Cancer Res 7:R204\u2013R209","journal-title":"Breast Cancer Res"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"15937","DOI":"10.1073\/pnas.252640799","volume":"99","author":"SJ Fleishman","year":"2002","unstructured":"Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A 99:15937\u201315940","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1006\/jmbi.1995.0599","volume":"254","author":"K Takano","year":"1995","unstructured":"Takano K, Ogasahara K, Kaneda H et al (1995) Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J Mol Biol 254:62\u201376","journal-title":"J Mol Biol"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/01.ede.0000083227.74669.7b","volume":"14","author":"JL Rutter","year":"2003","unstructured":"Rutter JL, Chatterjee N, Wacholder S et al (2003) The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 14:694\u2013700","journal-title":"Epidemiology"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s100380200019","volume":"47","author":"MM Ameyaw","year":"2002","unstructured":"Ameyaw MM, Tayeb M, Thornton N et al (2002) Ethnic variations in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 47:172\u2013175","journal-title":"J Hum Genet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0010-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0010-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0010-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:57Z","timestamp":1559233737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0010-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,26]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0010-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,26]]}}}